Cargando…
The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial
OBJECTIVE: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been reported to have beneficial effects in patients with IgA nephropathy (IgAN). Although DHA and EPA have different mechanisms of action, no study to date has assessed their individual actions in patients with IgAN. This st...
Autores principales: | Moriyama, Takahito, Kumon, Saeko, Kamiyama, Takahiro, Karasawa, Kazunori, Uchida, Keiko, Nitta, Kosaku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820033/ https://www.ncbi.nlm.nih.gov/pubmed/29093399 http://dx.doi.org/10.2169/internalmedicine.9155-17 |
Ejemplares similares
-
Severity of arterial and/or arteriolar sclerosis in IgA nephropathy and the effects of renin–angiotensin system inhibitors on its prognosis
por: Sugiura, Naoko, et al.
Publicado: (2021) -
A Novel Scoring System Based on Oxford Classification Indicating Steroid Therapy Use for IgA Nephropathy
por: Itami, Shusaku, et al.
Publicado: (2021) -
Primary IgA Vasculitis with Nephritis in a Patient with Rheumatoid Arthritis Diagnosed by Anti-galactose-deficient IgA1 Immunostaining
por: Karasawa, Kazunori, et al.
Publicado: (2019) -
Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors
por: Moriyama, Takahito, et al.
Publicado: (2020) -
Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids
por: Russell, Fraser D., et al.
Publicado: (2012)